Corroborating that data, in a model of psoriasis induced by IMQ, treatment with BML-111 reduced NF-κB activation and other clinical signs such as epidermal erythema, scaling, and thickening of the dorsal skin [22]. This evidence concerns the gene NFKB1 and psoriasis.